STX2 and hemolytic-uremic syndrome: Based on the interaction of Stx2 with the complement system [251], the C5-complement inhibiting monoclonal antibody Eculizumab was therapeutically employed as rescue therapy for EHEC–HUS patients, which had seizures or were in a stupor or coma [490].